Abraxis BioScience

Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes

Retrieved on: 
Wednesday, March 27, 2024
Cardiology, Civil service commission, Health, Cardiovascular disease, Pseudogene, Cell, Genetics, Mental, Abraxis BioScience, Patient, Female, Cancer, University, Biology, Biobank, Epigenome, Genomics, European Commission, Economics, Medicine, Pharmaceutical industry

MENLO PARK, Calif., March 27, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the University of Tartu, host of Estonia's National Biobank, has chosen the Revio HiFi sequencing system to sequence 10,000 whole human genomes and unlock new insights from its populational health data. The announcement follows funding from the European Commission and the Estonian government to help Estonia adopt personalized medicine at scale and adapt public health systems to the biology of its population. The University will also support the European Union's 1+ Million Genomes initiative, which seeks to boost innovation in healthcare across Europe.

Key Points: 
  • The University will also support the European Union's 1+ Million Genomes initiative , which seeks to boost innovation in healthcare across Europe.
  • 10,000 whole human genomes will be sequenced and analyzed by the Institute of Genomics at the University of Tartu using Revio.
  • "The team chose PacBio HiFi technology over other long- and short-read offerings because of its ability to sequence complete and accurate genomes at competitive economics and scale.
  • In addition to this 10,000-genome project, the Biobank team is looking to secure funding to sequence the entire biobank of over 200,000 samples to drive advances in health care globally.

PacBio Grants Equity Incentive Award to New Employee

Retrieved on: 
Friday, March 22, 2024
Employment, Pacific Ocean, Abraxis BioScience, Option, Effective date, Compensated emancipation, Effectiveness

The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).

Key Points: 
  • The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).
  • The Option has an exercise price of $3.67 per share, which is equal to the closing price of PacBio common stock on March 18, 2024 (the "Effective Date").
  • The Option and the RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the applicable award agreements thereunder entered into by the employee.
  • Vesting of the shares subject to each of the Option and the RSUs is conditioned upon the employee's continued service through each applicable vesting date.

Children's Mercy Kansas City and Geneyx Inc. Announce Collaboration to Advance Genomic Research and Analysis

Retrieved on: 
Wednesday, March 13, 2024
Genomics, Informatics, FACMG, Patient, Abraxis BioScience, CGC, DSM-IV codes, Research, Doctor of Philosophy, High fidelity, Mercy, Exome, Medical genetics, Nursing

and WILMINGTON, Del., March 13, 2024 /PRNewswire/ -- Children's Mercy Kansas City, one of the leading independent pediatric health organizations, and Geneyx Inc. are pleased to announce a collaboration aimed at advancing genomic research and analysis.

Key Points: 
  • and WILMINGTON, Del., March 13, 2024 /PRNewswire/ -- Children's Mercy Kansas City, one of the leading independent pediatric health organizations, and Geneyx Inc. are pleased to announce a collaboration aimed at advancing genomic research and analysis.
  • This collaboration formalized through a Master Software Subscription and Services Agreement, enables  Children's Mercy  to utilize Geneyx Analysis in its research institute to analyze, interpret, annotate, and report Long Read sequencing data originated by 5-base HiFi sequencing of PacBio technology.
  • "We are excited about this collaboration that signifies a significant step forward in leveraging cutting-edge technology to further genomic research and clinical care," said Emily Farrow, PhD, CGC, FACMG, Assistant Clinical Director, Clinical Genetics, Children's Mercy Kansas City.
  • Geneyx Analysis will play a crucial role in enhancing our ability to analyze and interpret long read genomic data, ultimately leading to advancements in pediatric healthcare."

Eckuity Capital Closes $150 Million Fund and Appoints New Partner - Top Clinical Oncologist, Dr Victoria Manax Rutson

Retrieved on: 
Tuesday, March 12, 2024
Partner, Fund, FDA, Pancreatic Cancer Action Network, Clinical trial, Pancreatic cancer, BMS, Abraxis BioScience, Investment, Pharmaceutical industry

NEW YORK, March 12, 2024 /PRNewswire/ -- Eckuity Capital, a New York and London-based growth and venture capital investor, has appointed Dr Victoria Manax Rutson (Dr Manax) as a new Partner of the company.

Key Points: 
  • NEW YORK, March 12, 2024 /PRNewswire/ -- Eckuity Capital, a New York and London-based growth and venture capital investor, has appointed Dr Victoria Manax Rutson (Dr Manax) as a new Partner of the company.
  • Dr Manax is an accomplished medical oncologist with over two decades of expertise in the pharmaceutical/biotech industry, focusing on global drug/device development, nanomedicines, and product launch /commercialization.
  • She has made indelible contributions to the field, particularly in shaping clinical trial landscapes with adaptive platform designs and biomarker integration.
  • Effectively overseeing numerous multimillion-dollar global clinical trial programs, Dr Manax holds multiple clinical advisories, chair positions, and patents, exemplifying her commitment to advancing medical science and patient well-being.

PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions

Retrieved on: 
Tuesday, March 12, 2024
Gene, Methylation, FTD, FMR1, ALS, Associate, Myotonic dystrophy, Abraxis BioScience, Huntington's disease, DNA, Apple IIe, Ataxia, Laboratory, University College London, Frontotemporal dementia, DSM-IV codes, Mosaic, High fidelity, Instability

MENLO PARK, Calif., March 12, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological disorders, including challenging-to-sequence genes with tandem repeat expansions. The new long-read workflow can minimize iterative analysis using legacy technology, and reduce the time needed to identify disease-causing variants and associated methylation signatures.

Key Points: 
  • "This product uses a differentiated method to do targeted long-read sequencing of DNA in its pure state.
  • Continuing the commitment to deliver comprehensive solutions, PacBio has prioritized delivering end-to-end workflows with their latest products.
  • The PureTarget Repeat Expansion Panel workflow utilizes the recently announced Nanobind PanDNA kit , ensuring robust results optimized for Revio and Sequel IIe users.
  • Customers can multiplex up to 48 samples on the PacBio Revio sequencing system and 24 samples on the PacBio Sequel IIe sequencing system.

GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

Retrieved on: 
Tuesday, February 20, 2024
Montefiore, VUS, Genetics in Medicine, Total, Legacy, Abraxis BioScience, Partnership, Exome, DSM-IV codes, WGS, Commercial, GAAP, American College, ACMG, Genome, Genetic testing, Medicaid, Genetics, Google Health, Medical genetics, Publication, NICU, Bank

ET

Key Points: 
  • ET
    STAMFORD, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the fourth quarter and full year of 2023.
  • Exome and genome represented 27% of all test results, up from 16% in the fourth quarter of 2022 and up from 23% in the third quarter of 2023.
  • Adjusted gross margin from continuing operations expanded to 56%, up from 41% in the fourth quarter of 2022 and up from 48% in the third quarter of 2023.
  • Excluding one-time items, representative continuing operations cash burn was $23.9 million in the fourth quarter of 2023.

PacBio to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, February 26, 2024
Abraxis BioScience, Conference

MENLO PARK, Calif., Feb. 26, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:

Key Points: 
  • MENLO PARK, Calif., Feb. 26, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
    TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 1:30 PM ET in Boston, MA
    Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 10:15 AM ET in Miami Beach, FL
    Live webcasts of the events can be accessed at the company's investors page at investor.pacificbiosciences.com.
  • Webcast replays will be available for at least 30 days following the event.

Molecular Assemblies Announces the Appointment of Two Industry Leaders to Its Commercial-Technology Advisory Board

Retrieved on: 
Tuesday, February 13, 2024
Therapy, Sigma-Aldrich, Epigenomics, Cornell University, MAI, Bruker, Abraxis BioScience, Principal, Biotechnology, Research, General partnership, Viridos (company), NGS, St. Louis, Biophysics, Protein engineering, Doctor of Philosophy, Gen-Probe, Synthetic biology, Gene editing, Cell biology, Dicarboxylic acid, Gene, Oligonucleotide, Thermo Fisher Scientific, Genomics, Horizon Discovery, CTAB, DNA, Fine chemical

"With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.

Key Points: 
  • "With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.
  • "Molecular Assemblies is helping accelerate the life science industry by removing one of the largest bottlenecks in R&D – the availability of long, pure, accurate oligonucleotides," said Todd C. Peterson, Ph.D., CTAB Chair and MAI Board Director.
  • He is currently Founder and Principal at GenApex Bio, a life sciences Board service and advisory practice.
  • His extensive experience includes leadership roles at Sigma-Aldrich and Genome Systems, where he made significant contributions to the genomics field.

seqWell Announces LongPlex Product to Address Multiplexing Challenges in Long Read Library Prep

Retrieved on: 
Monday, February 5, 2024
Biotechnology, Health, Genetics, Science, Research, Multiplexing, Whole genome sequencing, Marketing, Workflow, DNA, Abraxis BioScience, Entrepreneurship, Index, Genomics, Book

seqWell, a global provider of genomic library workflow solutions, today announced the early access availability of their new LongPlexTM 8kbp Multiplexing Kit, the company’s first product optimized to address workflow needs in long-read sequencing.

Key Points: 
  • seqWell, a global provider of genomic library workflow solutions, today announced the early access availability of their new LongPlexTM 8kbp Multiplexing Kit, the company’s first product optimized to address workflow needs in long-read sequencing.
  • LongPlex kits are designed to help researchers achieve a higher level of multiplexing with a simple enzymatic library barcoding workflow optimized for use with long read sequencers such as the PacBio Revio™ and Sequel II® systems.
  • seqWell has seen high customer demand for the LongPlex kits, which are now available in early access commercialization.
  • The early access configuration of the LongPlex kits are optimized for library workflows requiring fragments less than 10kbp, and designed to support a wide range of research applications including human long-read target capture assays, microbial genomics, and long read low-pass genotyping.

PacBio Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

Retrieved on: 
Monday, February 5, 2024
Workflow, Child, Metagenomics, Abraxis BioScience, DNAS, High fidelity, Organization

MENLO PARK, Calif., Feb. 5, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced two new high throughput library preparation kits and workflows optimized for its Revio sequencing system. With these kits, PacBio takes another leap forward in the long-read market by offering customers automated, scalable, and high-performance library preparation solutions with a 40 percent reduction in costs and a 60 percent decrease in workflow time. In addition, with the HiFi Plex Prep Kit 96 now including 384 validated barcode adapters, customers will have the groundbreaking ability to run 1,536 samples in a single Revio run.

Key Points: 
  • In addition, with the HiFi Plex Prep Kit 96 now including 384 validated barcode adapters, customers will have the groundbreaking ability to run 1,536 samples in a single Revio run.
  • We are thrilled with the prospect of providing customers with meaningful options for scale that allow them to explore emerging applications."
  • Engineered for efficiency, the new HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 are designed to allow users the ability to automate long-read sequencing workflow steps and streamline the process of preparing, pooling, and loading samples.
  • "The speed and ease of use of the HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 has made it possible for us to use long-read sequencing as a high-throughput genotyping tool."